Cochrane corner: convalescent plasma or hyperimmune immunoglobulin for people with COVID-19.
Pan Afr Med J
; 35(Suppl 2): 80, 2020.
Article
in English
| MEDLINE | ID: covidwho-948223
ABSTRACT
As the novel coronavirus continues to spread globally and across Africa, efforts are being accelerated to identify effective preventive and therapeutic measures to mitigate its burden. Convalescent plasma and hyperimmune immunoglobulin are being considered as potential therapeutic options for the coronavirus disease 2019 (COVID-19). We highlight and contextualize the findings of a recent Cochrane rapid review that evaluated the effectiveness and safety of convalescent plasma or hyperimmune immunoglobulin transfusion in the treatment of people with COVID-19. From the eight studies it included, the review found limited and low-certainty evidence on the effectiveness and safety of convalescent plasma therapy in patients with COVID-19. The evidence was limited by the small number of participants and low-quality of included studies, as well as the inconsistency of outcome measures and reporting across studies. As African countries brace for the further spread of the virus, while exploring potential therapeutic options to mitigate its morbidity and mortality at peak, convalescent plasma transfusion may offer a therapeutic ray of hope for the continent. Considering the limited evidence of the effectiveness and safety in the treatment of COVID-19, it is imperative for this therapy to be investigated within African contexts to ascertain not only its effectiveness and safety, but also its practical implications within the capacity of national blood transfusion services and health systems in the region.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
/
Reviews
Limits:
Humans
Country/Region as subject:
Africa
Language:
English
Journal:
Pan Afr Med J
Year:
2020
Document Type:
Article
Affiliation country:
Pamj.supp.2020.35.24157
Similar
MEDLINE
...
LILACS
LIS